Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders on June 4, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of April 14, 2026, holding 139,663,680 shares of common stock, may vote online using a 16-digit control number.
Three items are up for vote: electing two directors (Anand Mehra and Maxine Gowen) for terms ending in 2029, an advisory “say-on-pay” vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. The board is classified into three classes and currently has eight members, six of whom are independent under Nasdaq rules.
The proxy details 2025 pay for named executive officers, including total compensation of $3,375,591 for CEO Neal Walker, $1,490,790 for CFO Kevin Balthaser, and $1,447,106 for Chief Business Officer James Loerop, combining salary, stock awards, options and bonuses. It also discloses major shareholders such as BML Investment Partners at 10.2% and Biosion, Inc. at 8.1%, outlines board committee responsibilities, insider trading and clawback policies, and explains how votes, broker non-votes and quorum (69,831,841 shares) are determined.
Aclaris Therapeutics ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial interests in 7,626,705 shares of Aclaris common stock, representing 6.3% of the class based on 120,595,189 shares outstanding as of January 30, 2026. The filing states the Fund directly holds the 7,626,705 shares; RA Capital serves as investment adviser with shared voting and dispositive power over those shares. The Reporting Persons disclaim status as a group and include a statement that the Fund has delegated voting and disposition authority with a 61-day notice constraint.
Aclaris Therapeutics Inc receives an amended beneficial ownership filing from The Vanguard Group reporting 0 shares of Common Stock and 0% ownership in this amendment. The filing notes an internal realignment at Vanguard on January 12, 2026 that led certain subsidiaries and divisions to report separately under SEC Release No. 34-39538.
The filing is administrative: it states Vanguard and its covered accounts hold no beneficial shares of Aclaris Common Stock as reported and documents the change in reporting allocation among Vanguard entities. The signature block records filing execution by Ashley Grim, Head of Global Fund Administration.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report beneficial ownership of 9,345,000 shares of Aclaris Therapeutics common stock, representing 7.01% of the class as of March 16, 2026. The filing states the holders have shared voting and dispositive power over 9,345,000 shares and zero sole voting or dispositive power.
The filing explains the percent is calculated using 133,295,189 shares, derived from 120,595,189 shares outstanding as of January 30, 2026 plus 12.7 million shares sold under a sales agreement from March 2, 2026 through March 9, 2026. The report is a joint Schedule 13G filing under Rule 13d-1(k) and lists Deep Track Capital, LP as the relevant entity for control purposes.
Aclaris Therapeutics reported that on March 10, 2026 it sold 5.7 million shares of its common stock, generating $20.0 million in aggregate gross proceeds. The sale was made under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
The agents informed the company that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. The disclosure is furnished under Regulation FD and is not treated as filed for liability purposes under the Exchange Act.
Aclaris Therapeutics, Inc. reported that from March 2–9, 2026 it sold 12.7 million shares of its common stock through its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
These sales generated aggregate gross proceeds of $39.8 million and the shares were purchased by institutional investors, including Deep Track Capital. The disclosure is provided under Regulation FD and is expressly not deemed filed for liability purposes under Section 18 of the Exchange Act.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported equity compensation-related transactions on March 1, 2026. He exercised 2,375 Restricted Stock Units, which converted into 2,375 shares of common stock at a price of $0.0000 per share. Each restricted stock unit represents a contingent right to receive one share of common stock of the company.
To cover tax withholding obligations tied to the vesting and settlement of these units, 677 shares of common stock were withheld and disposed of at $2.87 per share, as indicated by transaction code F for tax-withholding disposition. After these transactions, Balthaser directly owned 187,453 shares of common stock.
Aclaris Therapeutics files its annual report describing a broad immuno-inflammatory pipeline and ongoing operating losses. The company is developing bosakitug and ATI-052 (anti-TSLP–based antibodies) plus oral ITK/JAK3 and ITK inhibitors for atopic dermatitis, asthma and other T cell–mediated diseases, alongside earlier-stage KINect discovery programs.
Aclaris reported net losses of $64.9 million in 2025 and $132.1 million in 2024, with an accumulated deficit of $967.8 million, funded mainly through equity and non-dilutive financing. Cash, cash equivalents and marketable securities totaled $151.4 million as of December 31, 2025, which management believes will fund operations for more than 12 months.
Aclaris Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its immuno-inflammatory pipeline. Net loss narrowed to $19.8 million in Q4 2025 from $96.6 million a year earlier, and to $64.9 million for 2025 from $132.1 million in 2024.
Total revenue was $1.3 million in Q4 2025 and $7.8 million for the year, reflecting lower licensing revenue after a 2024 milestone. R&D expenses rose to $52.6 million in 2025 as the company advanced bosakitug, ATI-052 and ATI-9494.
Cash, cash equivalents and marketable securities were $151.4 million as of December 31, 2025. Aclaris expects this to fund operations into the second half of 2028. The company reported positive interim Phase 1a data for ATI-052, initiated Phase 1b trials in atopic dermatitis and asthma, and plans a Phase 2 bosakitug readout and an IND filing for ATI-9494 in 2026.